Search: id:"swepub:oai:lup.lub.lu.se:daa49fd6-b2c7-4a45-af27-870ce7227d84" >
The Hidden Side of ...
-
Serrano, InmaculadaBellvitge University Hospital-IDIBELL
(author)
The Hidden Side of Complement Regulator C4BP : Dissection and Evaluation of Its Immunomodulatory Activity
- Article/chapterEnglish2022
Publisher, publication year, extent ...
-
2022-04-25
-
Frontiers Media SA,2022
Numbers
-
LIBRIS-ID:oai:lup.lub.lu.se:daa49fd6-b2c7-4a45-af27-870ce7227d84
-
https://lup.lub.lu.se/record/daa49fd6-b2c7-4a45-af27-870ce7227d84URI
-
https://doi.org/10.3389/fimmu.2022.883743DOI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:art swepub-publicationtype
-
Subject category:ref swepub-contenttype
Notes
-
C4b-binding protein (C4BP) is a well-known regulator of the complement system that holds additional and important activities unrelated to complement inhibition. Recently, we have described a novel immunomodulatory activity in the minor C4BP(β-) isoform directly acting over inflammatory phagocytes. Here we show that incorporation of the β-chain to the C4BP α-chain oligomer interferes with this immunomodulatory activity of C4BP. Moreover, an oligomeric form including only the complement control protein 6 (CCP6) domain of the C4BP α-chain (PRP6-HO7) is sufficient to “reprogram” monocyte-derived DCs (Mo-DCs) from a pro-inflammatory and immunogenic phenotype to an anti-inflammatory and tolerogenic state. PRP6-HO7 lacks complement regulatory activity but retains full immunomodulatory activity over inflammatory Mo-DCs induced by TLRs, characterized by downregulation of relevant surface markers such as CD83, HLA-DR, co-stimulatory molecules such as CD86, CD80 and CD40, and pro-inflammatory cytokines such as IL-12 and TNF-α. Furthermore, PRP6-HO7-treated Mo-DCs shows increased endocytosis, significantly reduced CCR7 expression and CCL21-mediated chemotaxis, and prevents T cell alloproliferation. Finally, PRP6-HO7 shows also full immunomodulatory activity over Mo-DCs isolated from lupus nephritis patients with active disease, even without further pro-inflammatory stimulation. Therefore PRP6-HO7, retaining the immunomodulatory activity of C4BP(β-) and lacking its complement regulatory activity, might represent a promising and novel alternative to treat autoimmune diseases.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Luque, AnaBellvitge University Hospital-IDIBELL
(author)
-
Mitjavila, FrancescaBellvitge University Hospital-IDIBELL
(author)
-
Blom, Anna M.Lund University,Lunds universitet,Institutionen för translationell medicin,Medicinska fakulteten,Proteinkemi, Malmö,Forskargrupper vid Lunds universitet,Department of Translational Medicine,Faculty of Medicine,Protein Chemistry, Malmö,Lund University Research Groups(Swepub:lu)klke-abl
(author)
-
Rodríguez de Córdoba, SantiagoCSIC Spanish National Research Council
(author)
-
Vega, M. CristinaCSIC Spanish National Research Council
(author)
-
Torras, JoanBellvitge University Hospital-IDIBELL
(author)
-
Aran, Josep M.Bellvitge University Hospital-IDIBELL
(author)
-
Bellvitge University Hospital-IDIBELLInstitutionen för translationell medicin
(creator_code:org_t)
Related titles
-
In:Frontiers in Immunology: Frontiers Media SA131664-3224
Internet link
Find in a library
To the university's database